hBD-1 vs Lixisenatide
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hBD-1 | Lixisenatide |
|---|---|---|
| Category | Dental & Oral | Weight Management |
| Full Name | Human beta-defensin 1 | Exendin-4-derived GLP-1 receptor agonist |
| Molecular Weight | 4490 Da | 4858 Da |
| Half-Life | minutes to hours | 2-4 hours |
| Amino Acids | 36 | 44 |
| Typical Dose | 1-10 µg/mL in experimental studies | 10-20 mcg daily |
| Route | Topical/Intraoral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 400 |
| Research Status | Pre-clinical | Approved |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.